Effectiveness of opicapone in Parkinson's disease patients with motor fluctuations according to baseline use of monoamine-oxidase-b inhibitors and dopamine agonists: The real-world OPTIPARK study

Abstract

Opicapone (OPC) proved to be effective in treating end-of-dose motor fluctuations (MF) in Parkinson's disease (PD) patients. The OPTIPARK study evaluated OPC 50 mg in a heterogeneous population of PD patients treated in real-world conditions. We evaluated the effectiveness of OPC in PD patients with MF according to baseline use of monoamine-oxidase-B inhibitors (MAO-Bi) and dopamine agonists (DA).